Rituximab treatment for immune thrombocytopenia associated with systemic lupus erythematosus;Traitement par rituximab d'un purpura thrombopénique immunologique au cours d'un lupus systémique

Annales de Dermatologie et de Venereologie

Volumn 133, Issue 1, 2006, Pages 53-55

  Lehembre, S ^a   Macario Barrel, A ^a   Musette, P ^a   Carvalho, P ^a   Joly, P ^a,b  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b HÔPITAL CHARLES NICOLLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA ANTIBODY; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RITUXIMAB; TUBERCULOSTATIC AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; EXPERIENCE; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; PATIENT; RELAPSE; SYSTEMIC LUPUS ERYTHEMATOSUS RASH; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT INDICATION; TUBERCULOSIS;

EID: 32044431886     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0151-9638(06)70845-6     Document Type: Article

References (16)

1. Cines DB, Blanchette VS. Immune thrombocytopenic Purpura. N Engl J Med 2002;346:995-1008.
2. Reff ME, Carner K, Chambers S, Chinn PC, Leonard JE, Raab R, et al. Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
3. Dupuy A, Viguier M, Bedane C, Cordoliani F, Blaise S, Aucouturier F, Bonnetblanc JM, et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 2004;140:91-6.
4. Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune haemolytic anemia, and Evans syndrome. Mayo Clin Proc 2003;78:1340-6.
5. Arnal C, Piette JC, Léone J, Taillan B, Hachulla E, Roudot-thoraval, et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 2002;2:75-83.
6. Maloney DG, Grillo-Lopez AJ, Withe CA, Bodkin DJ, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95.
7. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric and anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33.
8. Zaja F, Vianelli N, Sperotto A, Patriarca F, Tani M, Marin L, et al. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma 2003;44:1951-5.
9. Borradori L, Lombardi T, Samson J, Girardet C, Saurat JH, Hügli A. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20 follicular lymphoma-associated paraneoplasic pemphigus. Arch Dermatol 2001;137:269-72.
10. Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, et al. Rituximab for treatment of refractory autoimmune hemolytic anemia in children. Blood 2003;101:3857-61.
11. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001;98:952-7.
12. Shaw T, Quan J, Totoritis MC. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis 2003;62(Suppl 2):1155-9.
13. Stasi R. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood 2002;99:3872-3.
14. Perrotta S, Locatelli F, La Manna A, Cennamo L, De Stephano P, Nobili B. Anti-CD20 monoclonal antibody (rituximab) for life threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br Haematol J 2002;116:465-7.
15. Petschner F, Walker UA, Schmitt-Graff A, Uhl M, Peter HH. « Catastrophic systemic lupus erythematosus » with Rosai-Dorfman sinus histiocytosis. Successful treatment with anti-CD20/rituximab. Dtsch Med Wochenschr 2001;126:998-1001.
16. Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003;48:455-9.